世界の良性前立腺肥大症治療市場2021:メーカー別・地域別・種類別・用途別市場予測(~2026)

GlobalInfoResearchが発行した調査報告書(GIR21JY00001)
◆英語タイトル:Global Benign Prostatic Hyperplasia Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
◆商品コード:GIR21JY00001
◆発行会社(リサーチ会社):GlobalInfoResearch
◆発行日:2021年7月(※2024年版があります。お問い合わせください。)
◆ページ数:123
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2~3日)
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥1,030,080見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalInfoResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。

GlobalInfoResearch社の本調査レポートでは、良性前立腺肥大症治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。良性前立腺肥大症治療の種類別市場規模(医薬品、低侵襲手術、レーザー治療、その他)、用途別市場規模(病院、外来手術センター、専門クリニック、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・市場概要
・メーカー情報(企業概要、製品概要、販売量、価格、売上):Abbott、Allergan plc、Astellas Pharma、Asahi Kasei Corporation、Boehringer Ingelheim GmbH、GlaxoSmithKline、Pfizer、Sanofi、Teva Pharmaceutical Industries、Merck、Boston Scientific Corporation、Teleflex Incorporated、Endo International、Urologix、LISA Laser、Olympus
・メーカー別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年:医薬品、低侵襲手術、レーザー治療、その他
・用途別分析2016年-2026年:病院、外来手術センター、専門クリニック、その他
・良性前立腺肥大症治療の北米市場規模2016年-2026年:アメリカ、カナダ、メキシコ
・良性前立腺肥大症治療のヨーロッパ市場規模2016年-2026年:ドイツ、イギリス、フランス、ロシア、イタリア
・良性前立腺肥大症治療のアジア市場規模2016年-2026年:中国、日本、韓国、インド、東南アジア、オーストラリア
・良性前立腺肥大症治療の南米市場規模2016年-2026年:ブラジル、アルゼンチン
・良性前立腺肥大症治療の中東・アフリカ市場規模2016年-2026年:サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論
【レポートの概要】

The Benign Prostatic Hyperplasia Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Benign Prostatic Hyperplasia Treatment size is estimated to be USD 7574.7 million in 2026 from USD 6664.1 million in 2020, with a change XX% between 2020 and 2021. The global Benign Prostatic Hyperplasia Treatment market size is expected to grow at a CAGR of 3.3% for the next five years.

Market segmentation
Benign Prostatic Hyperplasia Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Drug Class
Minimally Invasive Surgeries
Laser Therapy
Others

Market segment by Application, can be divided into
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others

Market segment by players, this report covers
Abbott
Allergan plc
Astellas Pharma
Asahi Kasei Corporation
Boehringer Ingelheim GmbH
GlaxoSmithKline
Pfizer
Sanofi
Teva Pharmaceutical Industries
Merck
Boston Scientific Corporation
Teleflex Incorporated
Endo International
Urologix
LISA Laser
Olympus

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

【レポートの目次】

1 Market Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia Treatment
1.2 Classification of Benign Prostatic Hyperplasia Treatment by Type
1.2.1 Overview: Global Benign Prostatic Hyperplasia Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Type in 2020
1.2.3 Drug Class
1.2.4 Minimally Invasive Surgeries
1.2.5 Laser Therapy
1.2.6 Others
1.3 Global Benign Prostatic Hyperplasia Treatment Market by Application
1.3.1 Overview: Global Benign Prostatic Hyperplasia Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Specialty Clinics
1.3.5 Others
1.4 Global Benign Prostatic Hyperplasia Treatment Market Size & Forecast
1.5 Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast by Region
1.5.1 Global Benign Prostatic Hyperplasia Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Benign Prostatic Hyperplasia Treatment Market Size by Region, (2016-2021)
1.5.3 North America Benign Prostatic Hyperplasia Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Benign Prostatic Hyperplasia Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Benign Prostatic Hyperplasia Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Benign Prostatic Hyperplasia Treatment Market Drivers
1.6.2 Benign Prostatic Hyperplasia Treatment Market Restraints
1.6.3 Benign Prostatic Hyperplasia Treatment Trends Analysis
2 Company Profiles
2.1 Abbott
2.1.1 Abbott Details
2.1.2 Abbott Major Business
2.1.3 Abbott Benign Prostatic Hyperplasia Treatment Product and Solutions
2.1.4 Abbott Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Abbott Recent Developments and Future Plans
2.2 Allergan plc
2.2.1 Allergan plc Details
2.2.2 Allergan plc Major Business
2.2.3 Allergan plc Benign Prostatic Hyperplasia Treatment Product and Solutions
2.2.4 Allergan plc Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Allergan plc Recent Developments and Future Plans
2.3 Astellas Pharma
2.3.1 Astellas Pharma Details
2.3.2 Astellas Pharma Major Business
2.3.3 Astellas Pharma Benign Prostatic Hyperplasia Treatment Product and Solutions
2.3.4 Astellas Pharma Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Astellas Pharma Recent Developments and Future Plans
2.4 Asahi Kasei Corporation
2.4.1 Asahi Kasei Corporation Details
2.4.2 Asahi Kasei Corporation Major Business
2.4.3 Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Product and Solutions
2.4.4 Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Asahi Kasei Corporation Recent Developments and Future Plans
2.5 Boehringer Ingelheim GmbH
2.5.1 Boehringer Ingelheim GmbH Details
2.5.2 Boehringer Ingelheim GmbH Major Business
2.5.3 Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Product and Solutions
2.5.4 Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Boehringer Ingelheim GmbH Recent Developments and Future Plans
2.6 GlaxoSmithKline
2.6.1 GlaxoSmithKline Details
2.6.2 GlaxoSmithKline Major Business
2.6.3 GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Product and Solutions
2.6.4 GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 GlaxoSmithKline Recent Developments and Future Plans
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Benign Prostatic Hyperplasia Treatment Product and Solutions
2.7.4 Pfizer Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Pfizer Recent Developments and Future Plans
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Benign Prostatic Hyperplasia Treatment Product and Solutions
2.8.4 Sanofi Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Sanofi Recent Developments and Future Plans
2.9 Teva Pharmaceutical Industries
2.9.1 Teva Pharmaceutical Industries Details
2.9.2 Teva Pharmaceutical Industries Major Business
2.9.3 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Product and Solutions
2.9.4 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Teva Pharmaceutical Industries Recent Developments and Future Plans
2.10 Merck
2.10.1 Merck Details
2.10.2 Merck Major Business
2.10.3 Merck Benign Prostatic Hyperplasia Treatment Product and Solutions
2.10.4 Merck Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Merck Recent Developments and Future Plans
2.11 Boston Scientific Corporation
2.11.1 Boston Scientific Corporation Details
2.11.2 Boston Scientific Corporation Major Business
2.11.3 Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Product and Solutions
2.11.4 Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Boston Scientific Corporation Recent Developments and Future Plans
2.12 Teleflex Incorporated
2.12.1 Teleflex Incorporated Details
2.12.2 Teleflex Incorporated Major Business
2.12.3 Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Product and Solutions
2.12.4 Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Teleflex Incorporated Recent Developments and Future Plans
2.13 Endo International
2.13.1 Endo International Details
2.13.2 Endo International Major Business
2.13.3 Endo International Benign Prostatic Hyperplasia Treatment Product and Solutions
2.13.4 Endo International Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Endo International Recent Developments and Future Plans
2.14 Urologix
2.14.1 Urologix Details
2.14.2 Urologix Major Business
2.14.3 Urologix Benign Prostatic Hyperplasia Treatment Product and Solutions
2.14.4 Urologix Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Urologix Recent Developments and Future Plans
2.15 LISA Laser
2.15.1 LISA Laser Details
2.15.2 LISA Laser Major Business
2.15.3 LISA Laser Benign Prostatic Hyperplasia Treatment Product and Solutions
2.15.4 LISA Laser Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 LISA Laser Recent Developments and Future Plans
2.16 Olympus
2.16.1 Olympus Details
2.16.2 Olympus Major Business
2.16.3 Olympus Benign Prostatic Hyperplasia Treatment Product and Solutions
2.16.4 Olympus Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 Olympus Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Benign Prostatic Hyperplasia Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Benign Prostatic Hyperplasia Treatment Players Market Share
3.2.2 Top 10 Benign Prostatic Hyperplasia Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Benign Prostatic Hyperplasia Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Benign Prostatic Hyperplasia Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Benign Prostatic Hyperplasia Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Application (2016-2021)
5.2 Benign Prostatic Hyperplasia Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2026)
6.2 North America Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2026)
6.3 North America Benign Prostatic Hyperplasia Treatment Market Size by Country
6.3.1 North America Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2026)
6.3.2 United States Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2026)
7.2 Europe Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2026)
7.3 Europe Benign Prostatic Hyperplasia Treatment Market Size by Country
7.3.1 Europe Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2026)
7.3.2 Germany Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
7.3.3 France Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Region
8.3.1 Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Region (2016-2026)
8.3.2 China Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
8.3.5 India Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2026)
9.2 South America Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2026)
9.3 South America Benign Prostatic Hyperplasia Treatment Market Size by Country
9.3.1 South America Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Country
10.3.1 Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

...

【掲載企業】

Abbott、Allergan plc、Astellas Pharma、Asahi Kasei Corporation、Boehringer Ingelheim GmbH、GlaxoSmithKline、Pfizer、Sanofi、Teva Pharmaceutical Industries、Merck、Boston Scientific Corporation、Teleflex Incorporated、Endo International、Urologix、LISA Laser、Olympus

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の良性前立腺肥大症治療市場2021:メーカー別・地域別・種類別・用途別市場予測(~2026)(Global Benign Prostatic Hyperplasia Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026)]についてメールでお問い合わせはこちらでお願いします。